What is OM1?
OM1 operates at the intersection of artificial intelligence and healthcare, providing tech-enabled solutions for both prospective and retrospective evidence generation. The company's platform delivers AI-powered real-world data and insights crucial for personalized medicine and observational research. OM1 focuses on key specialty areas including immunology, mental health, and cardiometabolic health, catering to global companies that aim to improve patient care through sophisticated data analytics. Their commitment to innovation in real-world evidence (RWE) analytics has been recognized, positioning them as a leader in the field.
How much funding has OM1 raised?
OM1 has raised a total of $171M across 4 funding rounds:
Series A
$15M
Series B
$21M
Private Equity
$50M
Other Financing Round
$85M
Series A (2017): $15M with participation from 7wireVentures, Wanxiang Healthcare Investments, and General Catalyst
Series B (2018): $21M led by General Catalyst, 7wireVentures, and Polaris Partners
Private Equity (2019): $50M supported by 7wireVentures, General Catalyst (GC), BA Venture Partners, and Polaris Partners
Other Financing Round (2021): $85M featuring D1 Capital Partners, Breyer Capital, and Kaiser Permanente
Key Investors in OM1
D1 Capital Partners
D1 Capital Partners is an investment firm that likely focuses on significant capital deployment, given its participation in OM1's major funding rounds. Their involvement suggests a strategic interest in companies with high growth potential and disruptive technologies within the healthcare and data analytics sectors.
Breyer Capital
Breyer Capital is an independent global venture capital and private equity investor known for its long-term, idea-driven investments, particularly in artificial intelligence and machine learning. Their participation indicates a belief in OM1's AI-powered approach to healthcare data.
Kaiser Permanente
Kaiser Permanente, a leading not-for-profit integrated healthcare organization, brings extensive operational and clinical expertise. Their investment suggests a strategic alignment with OM1's mission to improve patient outcomes through real-world data and advanced analytics in healthcare delivery.
What's next for OM1?
With substantial enterprise-level backing and a recent strategic investment, OM1 is poised for significant expansion and innovation. The company's focus on AI-driven insights for personalized medicine and observational research aligns with the growing demand for data-centric healthcare solutions. Future developments are likely to involve further enhancement of their data networks, expansion into new therapeutic areas, and the deepening of partnerships with global healthcare companies. This strategic financing will empower OM1 to scale its operations, refine its AI capabilities, and solidify its position as a key player in transforming healthcare through advanced data analytics and evidence generation.
See full OM1 company page
